齐拉西酮与阿立哌唑治疗难治性精神分裂症疗效和安全性比较

The compare of effects and security of Ziprasidone and Aripiprazole in the treatment of refractory schizophrenia

目的:比较齐拉西酮与阿立哌唑对难治性精神分裂症的疗效和安全性。方法:将80例难治性精神分裂症患者随机分为两组,每组各40例,分别给予齐拉西酮和阿立哌唑治疗,疗程12周,用阳性症状和阴性症状量表(PANSS)评定疗效,用副反应量表(TESS)评定不良反应。结果:齐拉西酮组治疗有效率为67.5%,阿立哌唑组为70.0%,两组药物疗效比较无统计学差异(P>0.05)。两种药物的主要不良反应均为头痛、头晕,不良反应发生率无显著性差异(P>0.05),齐拉西酮组不良反应严重程度稍高于阿立哌唑。结论:齐拉西酮与阿立哌唑对难治性精神分裂症疗效相当,安全性高,不良反应轻,两药均有利于提高患者的生活质量及服药依从性。

Objective：To compare the effects and security of Ziprasidone and Aripiprazole in the treatment of refractory schizophrenic patients.Methods：A total of 80 patients with refractory schizophrenic were randomly divided into two groups,respectively,for Ziprasidone and Aripiprazole treatment,treatment for 12 weeks,with Positive Symptoms and Negative Symptoms Scale（PAN-SS） assessment of efficacy,adverse reactions with the scale（TESS） assessment of adverse reactions.Results： Ziprasidone in the treatment response rate was 63.7%,Aripiprazole 62.2%,overall efficacy difference between the two groups was,there were no significant differences in the effects（P〉0.05）,and the incidence rate side effects between the two drugs（P〉0.05）.The main side effects of both drugs are headache dizziness,etc.the of Ziprasidone are severer than that of the Aripiprazole group.Conclusions： Ziprasidone and Aripiprazole are similar in the treatment of refractory schizophrenic,safer with fewer side effects and can help improve the quality of life and medicating compliance of patients.